Company Filing History:
2 out of 9 
1 out of 1 Years Active: 2015-2018
Title: Innovations and Contributions of Guangjun Nie
Introduction
Guangjun Nie is a prominent inventor based in Beijing, China. He has made significant contributions to the field of biotechnology, particularly in the development of innovative treatments for tumors. With a total of three patents to his name, his work focuses on enhancing therapeutic strategies for cancer treatment.
Latest Patents
Guangjun Nie's latest patents include a tumor vascular disrupting agent polypeptide, gene, expression vector, and its use. This invention relates to a polypeptide that has the amino acid sequence as shown by SEQ ID NO: 1. The polypeptide comprises a truncated tissue factor (tTF) and a tumor-targeting molecule (pHLIP), which are connected by five amino acids. This design ensures that the functions of both components remain intact. The fusion protein can be positioned on the surface of tumor vascular endothelial cells, providing the blood coagulation feature of tTF in a tumor vessel, thereby disrupting the blood supply to the tumor area and aiding in treatment. Another significant patent involves an antigen composition, preparation method, and its application in tumor vaccines. This method includes steps to obtain a tumor antigen protein, induce immature dendritic cells to mature, and separate cell vesicles for vaccine preparation.
Career Highlights
Guangjun Nie has worked with notable organizations such as the National Center for Nanoscience and Technology and Beijing Hua'an Innovation Biotechnology Co., Ltd. His experience in these institutions has allowed him to advance his research and contribute to the field of cancer treatment.
Collaborations
Some of his notable coworkers include Suping Li and Yanhua Tian. Their collaborative efforts have further enhanced the research and development of innovative solutions in biotechnology.
Conclusion
Guangjun Nie's work exemplifies the impact of innovative research in the field of biotechnology, particularly in cancer treatment. His patents reflect a commitment to advancing medical science and improving therapeutic options for patients.